Dermatology

A modified Goeckerman regimen was associated with significant improvement of symptoms in patients with chronic, severe atopic dermatitis.

The two major causes of atopic dermatitis: dysfunctional dermal barrier and immune responses.

Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.

With plaque psoriasis becoming an increasingly common condition providers are able to more easily identify the condition than they had in the past. Looking for red scaling plaques, and thickened skin, as well as asking questions can get doctors the answers they need. In rare cases skin biopsies are also performed.

The days of patients with plaque psoriasis being treated with tar and special lights are fading as new agents, especially oral agents, are being developed.

Proactive administration of topical corticosteroid was found to reduce allergen sensitization in patients with atopic dermatitis (AD) as well as the periodic exacerbation of pruritic eczema.

For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.

When a patient is diagnosed with chronic idiopathic urticaria, there are several things doctors can do to help them. The process to get the proper diagnosis can take several weeks, which can complicate the situation for patients.

People can experience bouts of urticaria over the course of their lives, but usually they only last for a matter of days. When the symptoms last six weeks or more, it can be classified as chronic idiopathic urticaria.

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.

A review of studies concludes that switching psoriatic arthritis patients who have stopped responding to one tumor necrosis factor inhibitor (TNFi) to another will likely reduce their symptoms, but the effectiveness of each new medication will likely be less than each former medication.

A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.

Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.

Eric Simpson, MD, the lead author on the study, spoke to MD Magazine about the results, which showed great improvement with few side effects for those with moderate or severe atopic dermatitis.

Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.

The stem cells can be turned into brain cells in laboratories, which can give scientists a better understanding of the genes and characteristics of brain cells that bipolar disorder patients have.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.